Id |
Subject |
Object |
Predicate |
Lexical cue |
T222 |
1-12 |
NNP |
denotes |
Tocilizumab |
T223 |
12-13 |
-COMMA- |
denotes |
, |
T224 |
14-15 |
DT |
denotes |
a |
T225 |
16-26 |
JJ |
denotes |
monoclonal |
T226 |
27-35 |
NN |
denotes |
antibody |
T227 |
36-43 |
IN |
denotes |
against |
T228 |
44-47 |
NN |
denotes |
IL6 |
T229 |
47-48 |
-COMMA- |
denotes |
, |
T230 |
49-54 |
MD |
denotes |
could |
T231 |
55-61 |
VB |
denotes |
confer |
T232 |
62-70 |
JJ |
denotes |
clinical |
T233 |
71-78 |
NN |
denotes |
benefit |
T234 |
79-81 |
IN |
denotes |
in |
T235 |
82-90 |
NNS |
denotes |
patients |
T236 |
91-95 |
IN |
denotes |
with |
T237 |
96-100 |
JJ |
denotes |
high |
T238 |
101-104 |
NN |
denotes |
IL6 |
T239 |
105-111 |
NNS |
denotes |
levels |
T240 |
113-122 |
JJ |
denotes |
Essential |
T241 |
123-131 |
NNS |
denotes |
elements |
T242 |
132-136 |
IN |
denotes |
that |
T243 |
137-144 |
NN |
denotes |
process |
T244 |
145-154 |
NN |
denotes |
SARS-CoV2 |
R213 |
T222 |
T223 |
arg1Of |
Tocilizumab,"," |
R214 |
T226 |
T223 |
arg2Of |
antibody,"," |
R215 |
T226 |
T224 |
arg1Of |
antibody,a |
R216 |
T226 |
T225 |
arg1Of |
antibody,monoclonal |
R217 |
T226 |
T227 |
arg1Of |
antibody,against |
R218 |
T228 |
T227 |
arg2Of |
IL6,against |
R219 |
T231 |
T229 |
arg1Of |
confer,"," |
R220 |
T222 |
T230 |
arg1Of |
Tocilizumab,could |
R221 |
T231 |
T230 |
arg2Of |
confer,could |
R222 |
T222 |
T231 |
arg1Of |
Tocilizumab,confer |
R223 |
T233 |
T231 |
arg2Of |
benefit,confer |
R224 |
T233 |
T232 |
arg1Of |
benefit,clinical |
R225 |
T231 |
T234 |
arg1Of |
confer,in |
R226 |
T235 |
T234 |
arg2Of |
patients,in |
R227 |
T235 |
T236 |
arg1Of |
patients,with |
R228 |
T239 |
T236 |
arg2Of |
levels,with |
R229 |
T239 |
T237 |
arg1Of |
levels,high |
R230 |
T239 |
T238 |
arg1Of |
levels,IL6 |
R231 |
T241 |
T240 |
arg1Of |
elements,Essential |
R232 |
T241 |
T242 |
arg1Of |
elements,that |